<DOC>
	<DOCNO>NCT00462358</DOCNO>
	<brief_summary>This Phase 1 study patient advance solid tumor receive investigational study drug ARRY-520 . This study two part . In first part , patient advance solid tumor receive increase dos study drug , without granulocyte-colony stimulating factor ( G-CSF ) support , order achieve high dose possible cause unacceptable side effect . Approximately 15 patient ( per schedule ) US enrol Part 1 ( Completed ) . In second part study , patient receive best dose study drug determine first part study follow evaluate side effect study drug cause effectiveness , , treat cancer . Approximately 15 patient US enrol Part 2 ( Completed ) .</brief_summary>
	<brief_title>A Study ARRY-520 Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Key Histological cytological evidence malignancy . Advanced solid tumor recur progress follow standard therapy ( y ) . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 . Adequate hematology count serum chemistry value . Additional criterion exist . Key Treatment investigational product device , antineoplastic therapy ( exclusion hormone therapy therapy continue standard dose throughout study ) within 28 day prior first dose study drug . Major surgery within 28 day prior first dose study drug . Radiotherapy ( RT ) within 28 day prior first dose study drug ( except local RT &lt; 5 % bone marrow ) . Known positive serology human immunodeficiency virus ( HIV ) , hepatitis C , and/or active hepatitis B . Additional criterion exist .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>